ScholarIQanswers from OpenAlex & ORCID
John D. Hainsworth
ResearcherPublications, citations & collaboration network
John D. Hainsworth is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does John D. Hainsworth have?
ScholarIQindexed works
John D. Hainsworth has 789 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does John D. Hainsworth have?
ScholarIQcitation count
John D. Hainsworth has 58,031 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of John D. Hainsworth?
ScholarIQh-index
John D. Hainsworth has an h-index of 99 in OpenAlex.
What is the i10-index of John D. Hainsworth?
ScholarIQi10-index
John D. Hainsworth has an i10-index of 410 in OpenAlex.
What is the ORCID of John D. Hainsworth?
ScholarIQorcid
The ORCID for John D. Hainsworth is on the source record.
What is the OpenAlex record for John D. Hainsworth?
ScholarIQopenalex
The OpenAlex for John D. Hainsworth is on the source record.
What are the most-cited papers on John D. Hainsworth?
ScholarIQmost cited works
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher, Karim Fizazi, Fred Saad, Mary‐Ellen Taplin, Cora N. Sternberg, Kurt Miller, Ronald de Wit, Peter F.A. Mulders, Kim N., Neal D. Shore, Andrew J. Armstrong, Thomas W. Flaig, Aude Fléchon, Paul N. Mainwaring, Mark T. Fleming, John D. Hainsworth, Mohammad Hirmand, Bryan Selby, Lynn Seely, Johann S. de Bono
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. de Bono, Christopher J. Logothetis, Arturo Molina, Karim Fizazi, Scott North, Luis Chu, Kim N., Robert J. Jones, Oscar B. Goodman, Fred Saad, John Staffurth, Paul N. Mainwaring, Stephen Harland, Thomas W. Flaig, Thomas E. Hutson, Tina Cheng, Helen Patterson, John D. Hainsworth, Charles J. Ryan, Cora N. Sternberg, Susan Ellard, Aude Fléchon, Mansoor N. Saleh, Mark C. Scholz, Eleni Efstathiou, Andrea Zivi, Diletta Bianchini, Yohann Loriot, Nicole Chieffo, Thian Kheoh, Christopher M. Haqq, Howard I. Scher
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
Aleksandar Sekulić, Michael R. Migden, Anthony E. Oro, Luc Dirix, Karl D. Lewis, John D. Hainsworth, James Solomon, Simon Yoo, Sarah T. Arron, Philip Friedlander, Ellen S. Marmur, Charles M. Rudin, Anne Lynn S. Chang, Jennifer A. Low, Howard Mackey, Robert L. Yauch, Richard Graham, Josina C. Reddy, Axel Hauschild
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott, Mahrukh Huseni, Michael B. Atkins, Robert J. Motzer, Brian I. Rini, Bernard Escudier, Lawrence Fong, Richard W. Joseph, Sumanta K. Pal, James A. Reeves, Mario Sznol, John D. Hainsworth, W. Kimryn Rathmell, Walter M. Stadler, Thomas E. Hutson, Martin Gore, Alain Ravaud, Sergio Bracarda, Cristina Suárez, Riccardo Danielli, Viktor Gruenwald, Toni K. Choueiri, Dorothee Nickles, Suchit Jhunjhunwala, Elisabeth Piault‐Louis, Alpa Thobhani, Jiaheng Qiu, Daniel S. Chen, Priti S. Hegde, Christina Schiff, Gregg Fine, Thomas Powles
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
Marianne Pavel, John D. Hainsworth, Éric Baudin, Marc Peeters, Dieter Hörsch, Robert Winkler, Judith Klimovsky, David Lebwohl, Valentine Jehl, Edward M. Wolin, Kjell Öberg, Eric Van Cutsem, James C. Yao